pyridoxamine has been researched along with Disease Exacerbation in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diabetic nephropathy is the leading cause of end-stage renal disease, and both the incidence and prevalence of diabetic nephropathy continue to increase." | 2.46 | Potential new therapeutic agents for diabetic kidney disease. ( Bolton, WK; Turgut, F, 2010) |
| "Pyridoxamine is an inhibitor of advanced glycation end-product (AGE) formation derived from vitamin B(6)." | 2.43 | The next generation of diabetic nephropathy therapies: an update. ( Tuttle, KR; Williams, ME, 2005) |
| "At present there is no therapy for Alzheimer's Disease which completely stops the progressive dementia effecting late onset Alzheimer's Disease (AD) patients." | 1.46 | A unique and promising combination of medications for the treatment of Alzheimer's disease. ( Weinstein, JD, 2017) |
| "Pyridoxamine treatment, as single therapy, decreased the progression of albuminuria and glomerular lesions." | 1.33 | Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. ( Berho, M; Elliot, SJ; Plati, AR; Potier, M; Striker, GE; Striker, LJ; Zeng, YJ; Zheng, F, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Sengupta, P | 1 |
| Biswas, S | 1 |
| Roy, T | 1 |
| Weinstein, JD | 1 |
| Pena-Polanco, JE | 1 |
| Fried, LF | 1 |
| Turgut, F | 1 |
| Bolton, WK | 1 |
| Alderson, NL | 2 |
| Chachich, ME | 1 |
| Frizzell, N | 1 |
| Canning, P | 1 |
| Metz, TO | 1 |
| Januszewski, AS | 1 |
| Youssef, NN | 1 |
| Stitt, AW | 1 |
| Baynes, JW | 2 |
| Thorpe, SR | 2 |
| Williams, ME | 1 |
| Tuttle, KR | 1 |
| Zheng, F | 1 |
| Zeng, YJ | 1 |
| Plati, AR | 1 |
| Elliot, SJ | 1 |
| Berho, M | 1 |
| Potier, M | 1 |
| Striker, LJ | 1 |
| Striker, GE | 1 |
| Swaminathan, S | 1 |
| Shah, SV | 1 |
| Degenhardt, TP | 1 |
| Arrington, DD | 1 |
| Beattie, RJ | 1 |
| Basgen, JM | 1 |
| Steffes, MW | 1 |
4 reviews available for pyridoxamine and Disease Exacerbation
| Article | Year |
|---|---|
Established and Emerging Strategies in the Treatment of Chronic Kidney Disease.
Topics: Allopurinol; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bicarbonate | 2016 |
Potential new therapeutic agents for diabetic kidney disease.
Topics: Amides; Animals; Clinical Trials as Topic; Connective Tissue Growth Factor; Diabetic Nephropathies; | 2010 |
The next generation of diabetic nephropathy therapies: an update.
Topics: Animals; Diabetic Nephropathies; Disease Progression; Enzyme Inhibitors; Glycation End Products, Adv | 2005 |
Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease.
Topics: Biomarkers; Chronic Disease; Diabetic Nephropathies; Disease Progression; Drugs, Investigational; Gl | 2008 |
1 trial available for pyridoxamine and Disease Exacerbation
| Article | Year |
|---|---|
Comparative Study to Evaluate the Effect of Low-Protein Diet Supplementation with Taurine and N-Acetylcysteine, N-Acetylcysteine and Pyridoxamine Dihydrochloride in Preventing the Progression of Chronic Renal Failure in Patients with Non-Diabetic Kidney D
Topics: Acetylcysteine; Adult; Aged; Diet, Protein-Restricted; Dietary Supplements; Disease Progression; Fem | 2022 |
4 other studies available for pyridoxamine and Disease Exacerbation
| Article | Year |
|---|---|
A unique and promising combination of medications for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Dementia; Disease Progression; Drug Design; Drug Therapy, Combination; Hum | 2017 |
Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, E | 2004 |
Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepine | 2006 |
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
Topics: Animals; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Fem | 2002 |